Anika Therapeutics, Inc. — Q1 2013 Form 10-Q Summary
Business Context and Reporting Period
Anika develops, manufactures, and commercializes hyaluronic-acid-based products for tissue protection, healing, and repair across orthobiologics, dermal, surgical, ophthalmic, and veterinary markets. This unaudited report covers the three months ended March 31, 2013, compared with the three months ended March 31, 2012.
Financial Performance and Position
| Metric | Q1 2013 | Q1 2012 | Change |
|---|---|---|---|
| Total revenue | $15.25 million | $14.36 million | Up 6.2% |
| Product revenue | $14.49 million | $13.61 million | Up 6.5% |
| Operating income | $5.01 million | $3.06 million | Up 63.6% |
| Net income | $3.07 million | $1.91 million | Up 60.5% |
| Diluted EPS | $0.21 | $0.14 | Up $0.07 |
| Operating margin | 32.9% | 21.3% | Improved |
| Product gross margin | 66.6% | 52.9% | Improved |
| Net margin | 20.1% | 13.3% | Improved |
Orthobiologics revenue increased 11.5% to $11.28 million, driven primarily by U.S. ORTHOVISC demand. Veterinary revenue increased 53.0% to $1.05 million, largely due to distributor ordering timing. Dermal revenue declined 51.8% to $0.24 million, and ophthalmic revenue declined 29.9% to $0.93 million. U.S. product revenue represented approximately 80% of product revenue, compared with 76% in the prior-year quarter.
Product gross profit increased to $9.65 million from $7.20 million. Management attributed the improvement to elimination of duplicate manufacturing facility costs, manufacturing improvements, scale efficiencies, and favorable product mix. Research and development expense increased 3.2% to $1.58 million, while SG&A increased 17.8% to $3.95 million.
Cash provided by operating activities was $6.07 million, compared with cash used of $1.69 million in Q1 2012. The improvement reflected higher net income and a $6.37 million cash benefit from accounts receivable collections. Cash and equivalents increased to $50.97 million from $44.07 million at December 31, 2012. Working capital was approximately $68.0 million.
Total debt was $9.20 million at March 31, 2013, including $1.60 million current and $7.60 million long term. The debt bears interest at the company’s option based on LIBOR plus 1.25% or the lender’s prime rate. Quarterly principal payments are $0.4 million, with a final $5.2 million installment due December 31, 2015. Management stated that available financial resources are adequate for the next twelve months.
Material Changes Versus the Prior Comparable Period
- Revenue increased 6.2%, led by U.S. orthobiologics and higher HYVISC sales.
- Product gross margin expanded to 66.6% from 52.9%, primarily due to manufacturing efficiencies and product mix.
- Operating income and net income increased substantially despite higher SG&A and income tax expense.
- Operating cash flow improved by approximately $7.76 million year over year.
- The company recorded a $135,607 restructuring credit from the sale of previously impaired equipment; no restructuring charges were recorded in Q1 2012.
- The Abano Terme, Italy tissue-engineering facility closure was substantially advanced. The remaining restructuring accrual was $310,578 at March 31, 2013.
- Debt declined by $400,000 during the quarter through scheduled principal repayment.
- Foreign currency translation reduced comprehensive income by $749,450 in Q1 2013, compared with a $756,461 gain in Q1 2012.
Guidance, Outlook, Risks, and Unusual Items
- Management expects research and development spending to increase as CINGAL clinical activities and other pipeline programs progress.
- The company expected to begin CINGAL patient enrollment during the first half of 2013.
- MONOVISC’s U.S. PMA remained under FDA review following a January 2013 amendment submitted after the FDA upheld its prior non-approvable decision.
- Management expected 2013 ophthalmic revenue to be lower than 2012 under the Bausch & Lomb supply agreement.
- Management expected full-year HYVISC revenue to be comparable with 2012 and anticipated dermal revenue growth for 2013, although Q1 dermal sales were weak because of order timing.
- The company terminated its U.S. Hyalomatrix distribution agreement with Misonix and was seeking a replacement partner.
- The Genzyme patent litigation concerning MONOVISC was stayed. Management believes losses are not probable, and no accrual was recorded. DePuy Mitek assumed certain obligations related to the litigation.
- An arbitration proceeding with Fidia concerns indemnification related to the prior Merogel Injectable labeling issue and Fidia’s counterclaim concerning escrow shares. Management considers related losses not probable and recorded no accrual.
- Key risks include FDA and foreign regulatory approvals, product commercialization, intellectual-property litigation, dependence on distribution partners, market competition, foreign currency exposure, clinical-trial execution, and compliance with debt covenants.
- The filing states that disclosure controls were effective and that there were no material changes in internal control over financial reporting.
Important Facts for Investors to Verify
- Whether the unusually strong 66.6% product gross margin is sustainable given expected changes in product mix.
- The timing and probability of FDA approval for U.S. MONOVISC and the commercial implications of any further regulatory delay.
- Progress, cost, enrollment, and regulatory milestones for the CINGAL clinical program.
- The effect of lower ophthalmic revenue and the loss of the Hyalomatrix U.S. distribution partner.
- Remaining cash costs and completion timing for the Italian restructuring.
- Debt maturity and covenant requirements, including the $5.2 million final installment due in 2015 and exposure to variable interest rates.
- Developments in the stayed Genzyme litigation and Fidia arbitration, including any change in management’s assessment of potential loss.
- Whether accounts receivable collections and HYVISC revenue were affected by timing items that may not recur.